Reaction

Lung Adenocarcinoma reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,981 reports · 95 co-occurring drugs

As of the last recalculation, Lung Adenocarcinoma appears in 2,981 FAERS reports alongside 95 co-occurring drug terms. The strongest observed disproportionality signal is CRIZOTINIB (PRR 47.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Crizotinib	84	47.4	47.8
Pemetrexed	133	45.3	45.6
Erlotinib Hydrochloride	77	44.1	44.3
Pemetrexed Disodium	174	33.8	34.0
Erlotinib	46	33.7	33.8
Baricitinib	39	28.6	28.7
Gefitinib	24	18.7	18.8
Bendamustine Hcl	31	14.1	14.1
Osimertinib	63	14.0	14.0
Carboplatin	214	12.6	12.6
Atezolizumab	63	11.6	11.6
Cisplatin	100	9.2	9.2
Trametinib	29	8.5	8.5
Dabrafenib	25	8.3	8.4
Melphalan	26	8.0	8.1
Fludarabine Phosphate	44	7.9	7.9
Polatuzumab Vedotin	11	7.9	7.9
Nintedanib	34	7.6	7.7
Bevacizumab	130	7.6	7.6
Melphalan Hydrochloride	26	7.3	7.3
Everolimus Tablets	17	7.1	7.1
Telmisartan	18	7.1	7.1
Valganciclovir Hydrochloride Powder,	12	6.9	6.9
Bleomycin Sulfate	10	6.8	6.8
Paclitaxel (Aibumin-Bound)	78	6.8	6.8
Entecavir	11	6.6	6.6
Thiotepa	9	6.6	6.6
Itraconazole	11	6.6	6.6
Adalimumab-Fkjp	43	6.6	6.6
Docetaxel Anhydrous	61	6.4	6.4
Docetaxel	61	6.4	6.4
Paclitaxel	87	6.3	6.3
Adalimumab-Aaty	42	6.3	6.3
Febuxostat Tablets 40 Mg	9	6.2	6.2
Febuxostat Tablets 80 Mg	9	6.2	6.2
Lamivudine Oral	22	6.1	6.1
Prednisolone	150	6.1	6.1
Prednisolone Oral	150	6.1	6.1
Prednisolone Oral Solution	150	6.1	6.1
Loperamide Hcl	11	6.0	6.0
Imatinib	15	6.0	6.0
Gemcitabine	33	5.9	5.9
Timolol	10	5.8	5.8
Amlodipine Besylate And Valsartan	9	5.7	5.7
Adalimumab-Adaz	42	5.6	5.6
Pembrolizumab	82	5.6	5.6
Dexamethasone Sodium Phosphate	8	5.5	5.5
Methotrexate	296	5.3	5.3
Tofacitinib Citrate	10	5.3	5.3
Gemcitabine Hydrochloride	40	5.3	5.3
Methotrexate Sodium	336	5.3	5.3
Nebivolol	12	5.3	5.3
Obinutuzumab	12	5.1	5.1
Lamivudine	22	5.0	5.0
Rituximab	142	4.9	4.9
Loperamide Hydrochloride Oral	7	4.8	4.8
Doxorubicin	59	4.7	4.7
Tacrolimus	101	4.6	4.6
Sofosbuvir	13	4.6	4.6
Tacrolimus Ointment 0.1%	80	4.6	4.6
Tacrolimus Extended-Release Capsules	80	4.6	4.6
Imatinib Mesylate	18	4.5	4.5
Busulfan	10	4.4	4.5
Cyclophosphamide Injection, Solution	109	4.4	4.4
Cyclophosphamide	109	4.4	4.4
Cyclophosphamide For Injection	109	4.4	4.4
Cladribine	6	4.4	4.4
Infliximab	130	4.3	4.3
Febuxostat	10	4.2	4.2
Doxorubicin Hydrochloride	19	4.1	4.1
Granisetron	5	3.3	3.3
Golimumab	40	3.3	3.3
Abatacept	62	3.2	3.2
Etoposide	33	3.2	3.2
Azacitidine For	8	3.1	3.1
Azacitidine	13	3.1	3.1
Ustekinumab	41	2.8	2.8
Durvalumab	8	2.8	2.8
Guselkumab	14	2.7	2.7
Suvorexant	5	2.7	2.7
Upadacitinib	31	2.7	2.7
Peginterferon Beta-1A	5	2.7	2.7
Lenalidomide	153	2.6	2.6
Fingolimod Hcl	32	2.6	2.6
Tolvaptan	5	2.4	2.4
Teriflunomide	15	2.3	2.3
Pirfenidone	13	2.2	2.2
Natalizumab	56	2.2	2.2
Venetoclax	19	2.2	2.2
Axicabtagene Ciloleucel	3	2.1	2.1
Ofatumumab	10	2.1	2.1
Carfilzomib	8	2.0	2.0
Daratumumab	11	1.9	1.9
Ixekizumab	10	1.9	1.9
Emtricitabine And Tenofovir Alafenamide	3	1.8	1.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.